Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$0.96 USD
+0.01 (1.43%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $0.97 +0.01 (1.01%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Karyopharm Therapeutics Inc. [KPTI]
Reports for Purchase
Showing records 381 - 388 ( 388 total )
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Selinexor Update in NHL and MM Shows High Response Rates Maintained, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Selinexor Update in NHL and MM Shows High Response Rates Maintained, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov 17
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Q3:14 Earnings, KPTI Continuing to Aggressively Pursue Clinical Development of Selinexor, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov 10
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Initiating Coverage with an OUTPERFORM Rating and $50 Price Target, Novel Broad-Spectrum Anti-Tumor Inhibition of Nuclear Export
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D